Week In Review: China Biopharma Books $500 Million Of Deals To Start 2022
January 08, 2022 at 13:45 PM EST
AffaMed acquired greater China rights to an ophthalmic drug from Hanmi Pharma in an $145 million agreement. Sperogenix Therapeutics in-licensed China rights to vamorolone from Santhera in a deal valued at up to $124 million, plus royalties
